Relapsed or Refractory Lymphomas

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Lantern Pharma
Lantern PharmaDALLAS, TX
1 program
1
LP-284Phase 11 trial
Active Trials
NCT06132503Recruiting110Est. Nov 2028

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
Lantern PharmaLP-284

Clinical Trials (1)

Total enrollment: 110 patients across 1 trials

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

Start: Jan 2023Est. completion: Nov 2028110 patients
Phase 1Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 110 patients
1 companies competing in this space